Targeting eosinophils: severe asthma and beyond.

Caminati, Marco; Menzella, Francesco; Guidolin, Lucia; Senna, Gianenrico

Caminati, Marco; Menzella, Francesco; Guidolin, Lucia; Senna, Gianenrico.

Afiliação

Caminati M; Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.
Menzella F; Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona, Verona, Italy.
Guidolin L; Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.
Senna G; Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona, Verona, Italy.

Drugs Context ; 8: 212587, 2019.

Article em En | MEDLINE | ID: mdl-31391853

Palavras-chave

ABPA; EGPA; benralizumab; eosinophilic esophagitis; eosinophilic inflammation; mepolizumab; reslizumab; severe asthma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Drugs Context Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google